From Addiction to Infection: Managing Drug Abuse in the Context of HIV/AIDS in Africa

Taiwo Akindipe, Lolade Abiodun, Sylvia Adebajo, Rahman Lawal, Solomon Rataemane


People who use drugs are at higher risk of HIV: directly through the sharing of injecting equipment, indirectly through associated risk behavior, and physiologically through the substances’ impact on the immune system. Drug users, especially people who inject drugs (PWID) are a bridge to the general population. The treatment of drug addiction and provision of harm reduction interventions have impact on HIV transmission and incidence. Addiction treatment reduces the frequency of drug-related risky behaviors and enhances access and adherence to HIV treatment, resulting in fewer new infections. However, the drug policies of many African countries are punitive and hostile to harm reduction programs. These fuel criminalization of drug use and discrimination against the drug user thereby preventing individuals with drug addiction from accessing treatment programs. There is need to formulate policies aimed at protecting the rights of people with drug addiction and address the ethical aspects of treatment. (Afr J Reprod Health 2014; 18[3]: 47-54)


Keywords: Drug users, Drug addiction, Substance use, HIV infection, Africa



Les toxicomanes sont plus à risque d’être atteints par le VIH: directement à travers le partage de matériel d'injection, indirectement par l'intermédiaire des comportements à risque associés, et physiologiquement par l'impact des substances sur le système immunitaire. Les usagers de drogues, en particulier les personnes qui s'injectent des drogues (PSiD) sont un pont à la population générale. Le traitement de la toxicomanie et de la fourniture des interventions de la réduction des méfaits ont un impact sur la transmission et l'incidence du VIH. Le traitement de la toxicomanie réduit la fréquence des comportements à risque liés à la drogue et améliore l'accès et l'adhésion au traitement du VIH, ce qui entraîne moins de nouvelles infections. Cependant, les politiques pharmaceutiques de nombreux pays africains sont punitives et hostiles à nuire à des programmes de réduction. Ceux-ci alimentent la criminalisation  de l'usage des drogues et la discrimination contre les usagers de drogues qui empêchant ainsi  les toxicomanes d’avoir accès aux programmes de traitement. Il est nécessaire d'élaborer des politiques visant à protéger les droits des toxicomanes et d’aborder les aspects éthiques du traitement. (Afr J Reprod Health 2014; 18[3]: 47-54)


Mots-clés: Les usagers de drogue, de la toxicomanie, de toxicomanie, infection par le VIH, l'Afrique

Full Text:



Population Reference Bureau (PRB). World Population Data Sheet 2013. (Accessed August 22, 2014). Available at -data-sheet_eng.pdf United Nations Programme on HIV/AIDS (UNAIDS).

Dewing S, Plüddemann A, Myers B and Parry CDH.

Review of injection drug use in six African countries: Egypt, Kenya, Mauritius, Nigeria, South Africa and

Tanzania. Drugs: education, prevention and policy 2006; 13 (2): 121-137

Adinoff B. Neurobiologic Processes in Drug Reward and

Addiction. Harv Rev Psychiatry 2004; 12(6): 305– 320.

National Institute on Drug Abuse (NIDA). The Science of Drug Abuse and Addiction 2012. (Accessed April 23, 2014). Available at publications/media-guide/science-drug-abuseaddiction.

McCurdy SA, Ross MW, Williams ML, Kilonzo GP, Leshabari MT. Flashblood: blood sharing among female injecting drug users in Tanzania. Addiction 2010; 105(6): 1062 - 1070.

Calsyn DA, Cousins SJ, Hatch-Maillette MA, Forcehimes A, Mandler R, et al . Sex Under the Influence of

Drugs or Alcohol: Common for Men in Substance Abuse Treatment and Associated with High Risk

Sexual Behavior. Am J Addict. 2010; 19(2): 119–127.

Pechansky F, Woody G, Inciardi J, et al. HIV seroprevalence among drug users: an analysis of selected variables based on 10 years of data collection in Porto Alegre, Brazil. Drug Alcohol Depend. 2006; 82:S109–S113.

Ugen KE, Nyland SB. Injecting drugs of abuse and immunity: implications for HIV vaccine testing and efficacy. Springer Semin Immun. 2006; 28:281–287.

Nair MPN, Saiyed ZM, Nair N, Gandhi NH, Rodriguez

JW et al. Methamphetamine Enhances HIV-1

Infectivity in Monocyte Derived Dendritic Cells. J Neuroimmune Pharmacol. 2009; 4:129–139 DOI 10.1007/s11481-008-9128-0

NARHS. National HIV/AIDS and Reproductive Health Survey 2012. Abuja Nigeria: Federal Ministry of Health.

UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2012. Geneva: UNAIDS.

UNAIDS and WHO. Guidelines on Estimating the Size of Populations Most at Risk to HIV 2011. (Accessed April 20, 2014). Available at en/media/unaids/contentassets/restore/2011_ Estimating_Populations_en.pdf.

The International HIV/AIDS Alliance (IHAA) 2010. Who are vulnerable and most-at-risk populations? 2010 (Accessed April 20, 2014). Available at http://www. HIVAIDSAlliance_WhoareMARPS.pdf.

Degenhardt L and Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease . Lancet 2012; 379: 55–70.

Infectivity in Monocyte Derived Dendritic Cells by Suppressing microRNA-155. PLoS ONE 2013; 8(12): e83682. doi:10.1371/journal.pone.0083682

Kim SG, Jung JB, Dixit D, Rovner R Jr, Zack JA, Baldwin GC, et al. Cocaine exposure enhances permissiveness of quiescent T cells to HIV infection. J Leukoc Biol. 2013, 94(4): 835-43.

McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers T.J. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. 2001; 62, 111–123.

Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH Jr. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cultures. AIDS 1990; 4:869–873

Roy S and Loh HH. Effects of opioids on the immune system. Neuro- chem. Res. 1996; 21, 1375–1386.

Goumon, Y, Stefano GB, Aunis D, Metz-Boutigue MH. Implications of endogenous morphine in the communication between neuroendocrine and immune systems. Ann. N.Y. Acad. Sci. 2002; 971, 542 – 543.

Glasel, JA. The effects of morphine on cell proliferation. Prog. Drug Res. 2000; 55, 33–80.

Singhal PC, Sharma P, Kapasi AA, Reddy K, Franki N, Gibbons N. Morphine enhances macrophage apoptosis. J. Immunol. 1998; 160, 1886 – 1893.

Ansari AA. Drugs of abuse and HIV—a perspective. Journal of Neuroimmunology 2004; 147, 9–12.

Tucker JS, Burnam MA, Sherbourne CD, Kung FY and Gifford AL. Substance use and mental health correlates of non-adherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. American Journal of Medicine 2003; 114: 573-580.

Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med, 2002; 17 (5): 377-81.

de Jong BC, Prentiss D, McFarland W, et al. Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea. J Acquir Immune Defic Syndr, 2005; 38 (1): 43-6.

Vittinghoff E, Hessol NA, Bacchetti P, et al. Cofactors for HIV disease progression in a cohort of homosexual and bisexual men. J Acquir Immune Defic Syndr. 2001; 27:308–314.

Baum M.K, Rafie C, Lai S, Sales S, Page B, Campa A. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. Journal of Acquired Immune Deficiency Syndromes 2009; 50(1): 93-99.

Kapadia F, Vlahov D, Donahoe R.M, Friedland G. The Role of Substance Abuse in HIV Disease Progression: Reconciling Differences from Laboratory and Epidemiologic Investigations. Clinical Infectious Diseases 2005; 41:1027–34.

Kohli R, Lo Y, Howard AA, et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis 2005 Sep 15; 41 (6): 864-72

van Sighem AI, van de Wiel MA, Ghani AC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003 Oct 17; 17 (15): 2227-36

Antoniou T, Tseng AL. Interactions Between Recreational Drugs and Antiretroviral Agents. The Annals of Pharmacotherapy, 2002; 36:1598-613.

Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and γhydroxybutyrate. Arch. Intern. Med. 1999; 159: 22212224.

Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet 1998; 352: 1751-1752.

Flexner CW, Cargill VA, Sinclair J, Kresina TF, Cheever L. Alcohol use can result in enhanced drug metabolism in HIV pharmacotherapy. AIDS Patient Care STDS 2001; 15: 57-58.

Kosel BW, Aweeka FT, Benowitz NL et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002; 16: 543-550.

Grelotti DJ, Closson EF, Smit JA, et al. Whoonga: Potential recreational use of HIV antiretroviral medication in South Africa. AIDS Behav 2013; 18(3): 511- 518.

Grelotti DJ, Closson EF, Mimiaga MJ. Pre-treatment antiretroviral exposure from recreational use. Lancet Infect Dis 2013; 13(1): 10-12.

Gatch MB, Kozlenkov A, Huang RQ, et al. The HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacol 2013; 38(12): 2373- 2384.

Larkan F, Van Wyk B, Saris J. Of remedies and poisons: Recreational use of ARV drugs in the social imagination of South African carers. Afr Sociol Rev 2010; 14(2): 62-73.

IRIN. Injecting Drug Use and HIV transmission 2013. (Accessed on August 6, 2013). http://www.irinnews. org/pdf/pn/plusnews-media-fact-file-hiv-transmission. pdf.

Sohler NL, Wong MD, Cunningham WE, Cabral H, Drainoni ML, Cunningham CO. Type and pattern of illicit drug use and access to health care services for HIV-infected people. AIDS Patient Care STDS. 2007; 21 Suppl 1:S68-76.

Neale J, Tompkins C, Sheard L. Barriers to accessing generic health and social care services: a qualitative study of injecting drug users. Health and Social Care in the Community 2008; 16(2): 147–154.

Chander G, Himelhoch S, Fleishman JA, et al. HAART receipt and viral suppression among HIV- infected patients with co-occurring mental illness and illicit drug use. AIDS Care-Psychological and Socio-

Medical Aspects of HIV/AIDS. 2009; 21(5): 655–663.

Krusi A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. International Journal of Drug Policy. 2010; 21(1): 4–9.

Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Dependence 2000; 59: 17-31.

Metzger DS, Woody GE, O’Brien CP. Drug Treatment as HIV Prevention: A Research Update. J Acquir Immune Defic Syndr. 2010 December 1; 55(Suppl 1):


Committee on Pediatric AIDS. Reducing the Risk of HIV Infection Associated With Illicit Drug Use. Pediatrics

; 117 (2); 566 -571 DOI: 10.1542/peds.2005-

Hilton BA, Thompson R, Moore-Dempsey L, and Janzen RG. Harm reduction theories and strategies for control of human immunodeficiency virus: A review of the literature. Journal of Advance Nursing, 2000; 33(3): 357-370.

United Nations Office on Drugs and Crime (UNODC). Reducing the adverse health and social consequences of drug abuse: a comprehensive approach. UNODC; Vienna:2008.Available at: documents/prevention/Reducing-adverseconsequences-drug-abuse.pdf.

Wodak A, McLeod L. The role of harm reduction in controlling HIV among injecting drug users. AIDS. 2008; 22(Suppl 2): S81–S92.

Harm Reduction International. Global State of Harm Reduction 2012.(Accessed August 22, 2014).

Available at

Reid SR. Injection drug use, unsafe medical injections, and HIV in Africa: A systematic review. Harm Reduction Journal 2009; 6:24.

Wolfe D, Csete J. Political and systemic barriers increasing risk of HIV for injecting drug users in East Africa. Addiction 2010; 105(10): 1859.


  • There are currently no refbacks.